BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16435096)

  • 1. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
    Krismann M; Thattamparambil P; Simon F; Johnen G
    Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
    Cagle PT; Churg A
    Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Morphological diagnostics of malignant pleural mesothelioma].
    Junker K; Müller KM
    Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The separation of benign and malignant mesothelial proliferations.
    Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
    Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign pleural lesion and malignant mesothelioma.
    Klima M; Gyorkey F
    Virchows Arch A Pathol Anat Histol; 1977 Nov; 376(3):181-93. PubMed ID: 145715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
    Mayall FG; Goddard H; Gibbs AR
    J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleural biopsy in the diagnosis of malignant mesothelioma.
    Herbert A; Gallagher PJ
    Thorax; 1982 Nov; 37(11):816-21. PubMed ID: 7163999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of the pleura: what the pulmonologists need to know.
    Cagle PT; Allen TC
    Respirology; 2011 Apr; 16(3):430-8. PubMed ID: 21362105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign and malignant mesothelial lesions of the pleura: quantitative study.
    Ranaldi R; Marinelli F; Barbatelli G; Mariuzzi G; Marzocchi F; Mancini AM; Pisani E; Ansuini G; Ricci M
    Appl Pathol; 1986; 4(1-2):55-64. PubMed ID: 3580194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. My approach to the diagnosis of mesothelial lesions.
    Butnor KJ
    J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.